GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Total Stockholders Equity

Tvardi Therapeutics (LTS:0HTC) Total Stockholders Equity : £-6.25 Mil (As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Total Stockholders Equity?

Tvardi Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was £-6.25 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Tvardi Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was £-0.67. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Tvardi Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Tvardi Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Tvardi Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Total Stockholders Equity Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23
Total Stockholders Equity
-36.99 -49.03

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Sep24 Mar25
Total Stockholders Equity -36.99 -49.03 - -59.35 -6.25

Tvardi Therapeutics  (LTS:0HTC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Tvardi Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.249-0)/9.356
=-0.67

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Tvardi Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -6.249
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tvardi Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Total Stockholders Equity
Comparable Companies
CADL GOSS OCGN CRVS TSVT ALMS PHAT TERN HRTX PVLA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TVRD:USA 69C:Germany
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines